



PharmaMar group obtained a net profit of €3 million in the first half of 2018

- **PharmaMar group's revenues increased by 10.4% in the first half, up to €107 million**
- **The group generated an EBITDA of €7 million in the first half of the year, compared to €0.1 million in the same period in 2017.**

Madrid, July 26th, 2017: PharmaMar group (MSE: PHM) has recognized total revenue of €107 million in the first half of 2018, a 10.4% increase over the first half of 2017. The Oncology division recorded total revenue of €63.3 million, equal to a 23% increase over the same period of 2017. Of this income, €22.4 million was obtained from licenses and development agreements (compared to €5.4 million in the same period of 2017). This income includes €4.1 million (US\$ 5 million) from the agreement between PharmaMar and Seattle Genetics, as well as €3 million obtained from the termination of the agreement with Chugai Pharmaceutical on Zepsyre in Japan. In this respect as well, after the obligations undertaken by PharmaMar towards Chugai Pharmaceutical have been terminated, PharmaMar has recognized as income the part of payment received at the signing of the contract in December 2016 (€30 million) which was yet to be recognized and which, as of January 1, 2018, specifically €15.1 million.

The total revenues also include Yondelis[®] net sales, which amounted to €38.7 million in the first half of 2018 compared to €43.3 million in the same period of the previous year. This difference is mainly due to a decrease in sales of raw materials to our partners, as well as due to price erosion in some European countries.

Income from royalties paid by our partners Janssen Products and Taiho Pharmaceutical for the sale of Yondelis[®] in USA, Japan and the rest of the world, except the European Union, amounted to €2.3 million for the first half of 2018 (compared to €2.8 million as of June 2017).



Regarding the consumer chemicals division, sales amounted to €40.5 million in the first half of 2018, compared to €42.2 million as of June 2017. This slight decrease was mainly driven by lower sales of insecticides for domestic use due to heavy spring rains.

In the first half of 2018, the amount spent in R&D was €40 million, compared to 37 million in the same period last year. The increase was mainly covered by the oncology division, in particular by clinical trials with Zepsyre® (lurbinectedin), among which is the Phase III ATLANTIS trial for the treatment of small cell lung cancer (SCLC). The recruitment of 600 patients for this trial is nearly completed. Zepsyre® is also involved in other clinical trials, including a Phase II Monotherapy trial for the treatment of small cell lung cancer, which is currently under way. The preliminary results of this trial were presented in June, at the conference of the American Society of Clinical Oncology (ASCO) in Chicago.

As a result of the above, the group's EBITDA in the first half of 2018 was €7 million, compared to €0.1 million in the same period of the previous year, and the net profit attributable to the group was €3 million in the first six months of 2018 compared to €-7 million in the first half of 2017.

About PharmaMar

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has other clinical-stage programs under development for several types of solid and hematological cancers, Zepsyre® (PM1183), plitidepsin, PM184 and PM14. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium, Austria and the United States. PharmaMar fully owns other companies: GENOMICA, a leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at www.pharmamar.com.

Disclaimer

This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

Media Contact:



Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Digital Communication Manager mmartinez-cava@pharmamar.com Mobile: +34
606597464
Phone: +34 918466000

Investor Relations:

José Luis Moreno Martínez-Losa –Investor Relations & Capital Markets Director
investorrelations@pharmamar.com

Phone: +34 914444500

Or please visit our website at www.pharmamar.com

